CSL Limited
CSL Limited
Your view on CSL.AX
Overview
What the company does, where it operates, and who runs it.
About CSL Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gordon Naylor DipCompSc
- Headquarters
- 655 Elizabeth Street, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gordon Naylor DipCompSc
- Headquarters
- 655 Elizabeth Street, Melbourne, VIC, AU
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China.
The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments.
This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties.
In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for CSL Limited. Starting points for CSL Limited: EPS -AUD 5.28, beta 0.08 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for CSL Limited. CSL Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for CSL Limited. Trailing twelve-month EPS for CSL Limited stands at -AUD 5.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterSep 2025 | Next quarterDec 2025 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | $0.00 | $4.14 | $6.43 | $6.87 |
| Lowest estimate | $0.00 | $4.14 | $6.28 | $6.47 |
| Highest estimate | $0.00 | $4.14 | $6.83 | $7.14 |
| Number of analysts | 0 | 1 | 13 | 13 |
| A year ago | $5.531 | $6.421 | −$5.471 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterSep 2025 | Next quarterDec 2025 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | $7.45B | $8.51B | $16.38B | $16.89B |
| Lowest estimate | $7.45B | $8.51B | $15.84B | $16.55B |
| Highest estimate | $7.45B | $8.51B | $16.64B | $17.38B |
| Number of analysts | 1 | 1 | 17 | 17 |
| A year ago | $3.64B | $5.92B | $16.04B | — |
| Growth vs a year ago | +104.6% | +43.7% | +2.1% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for CSL Limited. CSL Limited has reported as a listed company since 1994. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | Healthcare | Biotechnology | $19.3B | ||
| INCYIncyte Corporation | Healthcare | Biotechnology | $23.4B | ||
| IONSIonis Pharmaceuticals, Inc. | Healthcare | Biotechnology | $4.4B | ||
| MRNAModerna, Inc. | Healthcare | Biotechnology | $78.9B | ||
| REGNRegeneron Pharmaceuticals, Inc. | Healthcare | Biotechnology | $95.2B | ||
| RVMDRevolution Medicines, Inc. | Healthcare | Biotechnology | $34.9B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PLRXPliant Therapeutics, Inc. | Healthcare | NASDAQ | $36.9M | ||
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $10.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $10.1M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $244.5M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $66.3M | ||
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $2.2M | ||
| PMNProMIS Neurosciences, Inc. | Healthcare | NASDAQ | $28.4M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $46.7M | ||
| POLBFPoolbeg Pharma PLC | Healthcare | OTC | $46.6M | ||
| PPBTPurple Biotech Ltd. | Healthcare | NASDAQ | $210,578 | ||
| PPCBPropanc Biopharma Inc. Common Stock | Healthcare | NASDAQ | $1.8M | ||
| PPTDFPeptiDream Inc. | Healthcare | OTC | $1.1B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.16% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.21% | |
| IEFAiShares Core MSCI EAFE ETF | $188.8B in assets | 0.27% | |
| EFAiShares MSCI EAFE ETF | $75.5B in assets | 0.31% | |
| EWAiShares MSCI Australia ETF | $1.2B in assets | 4.75% | |
| EPPiShares MSCI Pacific ex Japan ETF | $2.2B in assets | 3.01% | |
| GCOWPacer Global Cash Cows Dividend ETF | $3.7B in assets | 1.44% | |
| PBPHPortfolio Building Block World Pharma and Biotech Index ETF | $1.4B in assets | 1.29% | |
Largest holders first, then the funds most concentrated in CSL.AX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold CSL Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for CSL Limited. Coverage tracks CSL Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of CSL Limited.